Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 01 October 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Metabolic syndrome increases the risk of liver fibrosis progression in chronic hep B

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B, reports the latest issue of Alimentary Pharmacology & Therapeutics.

News image

Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB).

Dr Wong and colleagues from China investigated the effects of coincidental metabolic syndrome on liver fibrosis progression in treatment-naïve chronic hepatitis B patients.

A total of 1466 chronic hepatitis B patients underwent liver stiffness measurement (LSM) by transient elastography in 2006–2008.

The researchers reported that 663 patients remained treatment-naïve, and had second LSM in 2010–2012.

Liver fibrosis progression was defined as an increase in liver stiffness measurement ≥30% at the second assessment.

16% of patients developed liver fibrosis progression
Alimentary Pharmacology & Therapeutics

The impact of coincidental metabolic syndrome and its factors on liver fibrosis progression were evaluated after adjustment for viral load and hepatitis activity.

At baseline, the mean age was 43 years, 55% were males, serum alanine aminotransferase (ALT) was 44 IU/L, HBV DNA was 4 log IU/mL, and liver stiffness measurement was 6.3 kPa.

The researchers diagnosed metabolic syndrome in 12%, and 21% patients at baseline and follow-up visit, respectively.

The team found that 13% and 3% of patients had coincidental and resolved metabolic syndrome, at baseline and follow-up, respectively.

After an interval of 44 months, the researchers observed that 16% of patients developed liver fibrosis progression.

Coincidental metabolic syndrome, central obesity and low level of high-density lipoprotein cholesterol were associated with liver fibrosis progression independent of change in viral load and ALT level.

The research team noted effects of coincidental metabolic syndrome were most apparent in the immune-tolerant phase.

Dr Wong's team concludes, "Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B infection, independent of viral load and hepatitis activity."

Aliment Pharmacol Ther 2014: 39(8): 883–893
02 April 2014

Go to top of page Email this page Email this page to a colleague

 30 September 2016 
Gluten breakdown and immunogenicity in celiac disease
 30 September 2016 
Noninvasive detection of NASH
 30 September 2016 
CEA levels to detect recurrent colorectal cancer
 29 September 2016 
Biologic therapies in IBD
 29 September 2016 
Predicting the prognosis of gastric cancer
 29 September 2016 
Predicting symptomatic outcomes in GERD
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us